4,875 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Purchased by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 4,875 shares of the company’s stock, valued at approximately $309,000.

Several other large investors have also modified their holdings of the business. Teacher Retirement System of Texas increased its holdings in Disc Medicine by 8.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock valued at $308,000 after buying an additional 396 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after acquiring an additional 593 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Disc Medicine by 2.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock valued at $1,428,000 after acquiring an additional 771 shares during the period. Rhumbline Advisers raised its position in shares of Disc Medicine by 5.7% in the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company’s stock worth $1,841,000 after acquiring an additional 1,553 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of Disc Medicine by 18.0% during the 3rd quarter. MetLife Investment Management LLC now owns 11,377 shares of the company’s stock worth $559,000 after purchasing an additional 1,735 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Insider Activity at Disc Medicine

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $62.75, for a total transaction of $470,625.00. Following the completion of the transaction, the insider now owns 14,035 shares in the company, valued at approximately $880,696.25. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 13,012 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $61.95, for a total value of $806,093.40. Following the completion of the sale, the chief executive officer now owns 72,065 shares in the company, valued at $4,464,426.75. The trade was a 15.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 382,202 shares of company stock worth $20,924,812 over the last quarter. Insiders own 4.24% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the topic of several analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Wedbush reissued an “outperform” rating and set a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Stifel Nicolaus lifted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Finally, TD Cowen assumed coverage on Disc Medicine in a research report on Thursday, February 27th. They set a “buy” rating on the stock. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Buy” and an average target price of $93.80.

Disc Medicine Price Performance

Shares of IRON opened at $52.47 on Friday. The company’s fifty day moving average price is $54.75 and its 200-day moving average price is $56.10. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $68.73. The firm has a market capitalization of $1.81 billion, a PE ratio of -13.18 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.08. As a group, research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.